VOLUME 23 NUMBER 3 | SUMMER 2023
A publication of the International Myeloma Foundation
14th Annual Summit of the IMF’s IMWG Top experts in myeloma focus on MGUS, SMM, MRD, frontline therapy, relapse, as well as new and emerging immunotherapies
ALSO IN THIS EDITION:
Key Myeloma Abstracts from 2023 ASCO & EHA
CAR T-cell therapy in the setting of earlier relapse
IMF Honors Two Outstanding Researchers
Exciting data presented on immuno therapies and the management of patients with relapsed myeloma, and much more! PAGE 8
Clinical trial data presented at ASCO and EHA demonstrate the promise of CAR T-cell therapies earlier in the course of myeloma PAGE 9
Dr. Mateos is recipient of the Robert A. Kyle Lifetime Achievement Award and Dr. Martin receives the Brian G.M. Durie Outstanding Achievement Award PAGE 10
This edition of Myeloma Today is supported by AbbVie • Amgen • Bristol Myers Squibb • GSK • Janssen Oncology • Karyopharm Therapeutics • Sanofi • Takeda Oncology